arXiv.itsnick.co

an independent field guide to 23 million papers from arXiv & OpenAlex — not affiliated with arXiv.org

Author

Lars Frison

3 papers · 1992–2025

1992: 11993: 01994: 01995: 01996: 01997: 11998: 01999: 02000: 02001: 02002: 02003: 02004: 02005: 02006: 02007: 02008: 02009: 02010: 02011: 02012: 02013: 02014: 02015: 02016: 02017: 02018: 02019: 02020: 02021: 02022: 02023: 02024: 02025: 1
1992peak 1 in 19922025

Frequent co-authors

Papers

showing 1–3 of 3 RSS

Repeated measures in clinical trials: Analysis using mean summary statistics and its implications for design

Lars Frison, Stuart Pocock

Statistics and Probability · Statistics in Medicine · · cited 605× · DOI ↗ · more like this ·

This paper explores the use of simple summary statistics for analysing repeated measurements in randomized clinical trials with two treatments. Quite often the data for each patient may be effectively summarized by a pre-treatment mean and a post-treatment mean. Analysis of covariance is the method of choice and its superiority over analysis of post-treatment means or analysis of mean changes is quantified, as regards both reduced variance and avoidance of bias, using a simple model for the covariance structure between time points. Quantitative consideration is also given to practical issues in the design of repeated measures studies: the merits of having more than one pre-treatment measurement are demonstrated, and methods for determining sample sizes in repeated measures designs are provided. Several examples from clinical trials are presented, and broad practical recommendations are…

Linearly divergent treatment effects in clinical trials with repeated measures: efficient analysis using summary statistics

Lars Frison, Stuart Pocock

Statistics and Probability · Statistics in Medicine · · cited 51× · DOI ↗ · more like this ·

In many randomized clinical trials with repeated measures of a response variable one anticipates a linear divergence over time in the difference between treatments. This paper explores how to make an efficient choice of analysis based on individual patient summary statistics. With the objective of estimating the mean rate of treatment divergence the simplest choice of summary statistic is the regression coefficient of response on time for each subject (SLOPE). The gains in statistical efficiency imposed by adjusting for the observed pre-treatment levels, or even better the estimated intercepts, are clarified. In the process, we develop the optimal linear summary statistic for any repeated measures design with assumed known covariance structure and shape of true mean treatment difference over time. Statistical power considerations are explored and an example from an asthma trial is used…

Use of eGFR Slope Thresholds as End Point Components in a Kidney Disease Progression Hierarchical Composite End Point

Niels Jongs, Samvel B. Gasparyan, Lars Frison +4 more

Statistics and Probability · Journal of the American Society of Nephrology · · cited 2× · DOI ↗ · more like this ·

Key Points It is feasible to apply eGFR thresholds in kidney progression hierarchical composite end point (HCE) to minimize variability impact on patient comparisons. Use of eGFR thresholds did not change treatment effect estimates of the kidney progression HCE in seven major CKD trials compared with no threshold. Applying eGFR thresholds had minimal effect on statistical power of the kidney progression HCE across various sample sizes. Background We developed and validated a kidney disease progression hierarchical composite end point (HCE) combining time-to-event end points with the rate of eGFR decline (eGFR slope) as a continuous end point. An alternative to this continuous end point is to apply various thresholds on an absolute and relative scale for the pairwise comparisons in the eGFR slope component. We assessed the effect of different thresholds on the treatment effects and…